Powerpack

Unlock full stockrow access for only $9.90/month and boost yourself as an investor.

  • Full quarterly history

    Every quarter and TTM period we hold, not just the last 12.

  • Analyst estimates

    Three years of forward estimates and dividend forecasts.

  • Unlimited screener

    All results, unlimited saved screens, email when a screen changes.

  • Unlimited Excel

    Full workbooks and screener exports.

  • Unlimited follows

See Powerpack
Screener Weekly Summary Pricing

InterCure Ltd. (INCR) vs SCYNEXIS, Inc. (SCYX)

InterCure Ltd. and SCYNEXIS, Inc. are both Drug Manufacturers Specialty & Generic companies. InterCure Ltd. is the larger, with a market value of $62.3M against $45.0M — 1.4× the size. SCYNEXIS, Inc. has negative trailing earnings, so its P/E is not meaningful; InterCure Ltd. trades at 9.8×. SCYNEXIS, Inc. grew revenue faster over the last twelve months: 682.5% against 16.2%. InterCure Ltd. has the higher net margin (4.88% vs −49.7%) and the higher return on invested capital (0.00% vs −110.7%). Across the 18 metrics below, InterCure Ltd. leads on 10 and SCYNEXIS, Inc. on 8.

Valuation

Metric INCR SCYX Drug Manufacturers Specialty & Generic median
P/E 9.84 n/m 20.14
P/S 1.98 2.52 2.25
P/B 1.96 0.78 1.90
Price to free cash flow n/m n/m 16.54
EV/EBITDA 23.47 n/m 12.29
EV/Sales 2.12 1.15 2.56
Earnings yield 10.16% (47.61%) (2.99%)
Free cash flow yield (0.34%) (25.67%) 0.00%

Profitability

Metric INCR SCYX Drug Manufacturers Specialty & Generic median
Gross margin 32.74% 100.00% 53.94%
Operating margin 0.00% (109.90%) 0.00%
Net margin 4.88% (49.74%) 0.00%
Free cash flow margin 0.00% (64.67%) 0.00%
Return on equity 0.00% (18.38%) (0.40%)
Return on assets 0.00% (15.09%) (3.32%)
Return on invested capital 0.00% (110.72%) 0.00%

Growth

Metric INCR SCYX Drug Manufacturers Specialty & Generic median
Revenue growth (TTM) 16.15% 682.47% 10.01%
EPS growth (last fiscal year) 52.50% 61.36% —
Revenue growth, 5-year CAGR 31.11% 179.40% 6.74%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric INCR SCYX Drug Manufacturers Specialty & Generic median
Debt to equity 0.27 0.00 0.05
Current ratio 1.85 9.65 2.31
Net debt to EBITDA (4.07) 2.54 0.85

Dividend

Metric INCR SCYX Drug Manufacturers Specialty & Generic median
Dividend yield — — 1.70%
Payout ratio 0.00 0.00 0.00

Size

Metric INCR SCYX Drug Manufacturers Specialty & Generic median
Market cap 62.33m 44.98m 337.35m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack